{"protocolSection":{"identificationModule":{"nctId":"NCT02998996","orgStudyIdInfo":{"id":"EURO 15-11"},"organization":{"fullName":"Eurocine Vaccines AB","class":"INDUSTRY"},"briefTitle":"Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU","officialTitle":"A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU"},"statusModule":{"statusVerifiedDate":"2018-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-09"},"primaryCompletionDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"completionDateStruct":{"date":"2017-06-01","type":"ACTUAL"},"studyFirstSubmitDate":"2016-11-10","studyFirstSubmitQcDate":"2016-12-16","studyFirstPostDateStruct":{"date":"2016-12-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-10-08","resultsFirstSubmitQcDate":"2018-10-08","resultsFirstPostDateStruct":{"date":"2019-02-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2018-10-08","lastUpdatePostDateStruct":{"date":"2019-02-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eurocine Vaccines AB","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The main purpose of the this study is to evaluate the safety and tolerability of Immunose™ FLU based on Endocine™ and quadrivalent influenza antigen."},"conditionsModule":{"conditions":["Influenza, Human"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":162,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Immunose™ FLU 1%,","type":"EXPERIMENTAL","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™","interventionNames":["Biological: 15 µg HA/strain and 1% Endocine™"]},{"label":"Immunose™ FLU 2%,","type":"EXPERIMENTAL","description":"15 µg HA/strain and 2% Endocine™","interventionNames":["Biological: 15 µg HA/strain and 2% Endocine™"]},{"label":"Influenza antigen,","type":"EXPERIMENTAL","description":"15 µg HA/strain","interventionNames":["Biological: 15 µg HA/strain"]},{"label":"Saline (NaCl),","type":"PLACEBO_COMPARATOR","description":"Placebo","interventionNames":["Biological: Placebo, Saline"]},{"label":"i.m. comparator,","type":"ACTIVE_COMPARATOR","description":"15 µg HA/strain","interventionNames":["Biological: intramuscular comparator"]},{"label":"i.n. comparator","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: intranasal comparator"]}],"interventions":[{"type":"BIOLOGICAL","name":"15 µg HA/strain and 1% Endocine™","description":"intranasal administration","armGroupLabels":["Immunose™ FLU 1%,"]},{"type":"BIOLOGICAL","name":"15 µg HA/strain and 2% Endocine™","description":"intranasal administration","armGroupLabels":["Immunose™ FLU 2%,"]},{"type":"BIOLOGICAL","name":"15 µg HA/strain","description":"intranasal administration","armGroupLabels":["Influenza antigen,"]},{"type":"BIOLOGICAL","name":"intramuscular comparator","description":"intramuscular administration","armGroupLabels":["i.m. comparator,"]},{"type":"BIOLOGICAL","name":"intranasal comparator","description":"intranasal administration","armGroupLabels":["i.n. comparator"]},{"type":"BIOLOGICAL","name":"Placebo, Saline","description":"intranasal administration","armGroupLabels":["Saline (NaCl),"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Local Tolerability - First Dose","description":"Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.","timeFrame":"Pre-dose, and 15 and 120 min after study drug administration (Visit 2)."},{"measure":"Local Tolerability - Second Dose (Group 1-4 Only)","description":"Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.","timeFrame":"Pre-dose, and 15 and 120 min after second study drug administration (Visit 3)."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent prior to any study related procedures.\n* Male or female 18-39 years of age (both inclusive) at screening\n* Subjects who the Investigator believes will comply with the requirements of the protocol.\n* BMI: 18.0 and 30.0 kg/m2 (inclusive).\n* Judged by the Investigator to have no serious illness based on medical history, physical examination, ECG, vital signs and blood and urine assessments at screening.\n* From the signing of the informed consent until 2 months after the last vaccination (Visit 3 for group 1 to 4 and Visit 2 for group 5 and 6) female subjects have to use contraceptive methods with a failure rate of \\< 1% to prevent pregnancy (combined \\[oestrogen and progestogen containing\\] hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal, transdermal\\], progestogen- only hormonal contraception associated with inhibition of ovulation \\[oral, injectable, implantable\\], intrauterine device \\[IUD\\], intrauterine hormone-releasing system \\[IUS\\], bilateral tubal occlusion, sexual abstinence). Any male partner should be willing to use condom or should be vasectomized.\n\nExclusion Criteria:\n\n* Diagnosis of laboratory-confirmed influenza in the 2015/2016 season.\n* Use of any investigational drug product within 3 months before screening or planned use during the study period, including the safety follow-up.\n* Administration of an influenza vaccine during the 6 months before screening.\n* Previously received another vaccine within 28 days before administration of the study vaccine, or is scheduled to receive another vaccine during the study period, excluding the safety follow-up.\n* Any contra-indication to intramuscular administration of the influenza vaccine AdimFlu-S according to its prescribing information.\n* Any contra-indication to administration of the influenza vaccine Fluenz Tetra according to its summary of product characteristics (SmPC).\n* History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to eggs or egg product as well as ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin, gentamycin and neomycin sulphate).\n* Diagnosis of asthma with poor disease control as assessed by the Investigator.\n* Potent immunosuppressive therapy including cytostatics, antibodies, drugs acting on immunophilins, interferons and other drugs used to prevent rejection of organ transplants, within 6 months before screening.\n* Use of any parenteral or oral corticosteroids within 30 days prior to screening. Inhaled steroids are allowed.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.\n* Any progressive or severe neurologic disorder, seizure disorder or Guillain-Barré syndrome.\n* History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.\n* Received blood, blood products and/or plasma derivatives or any administration of immunoglobulin preparation within the three months prior to Visit 2, or planned during the study.\n* Participation in blood donation within 3 months or plasma donation within 1 month prior to Visit 2.\n* History of substance or alcohol abuse within the past 2 years.\n* History or any illness/condition that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.\n* Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.\n* Pregnant or lactating female or intent to become pregnant during the clinic phase (up until and including Visit 4 for group 1 to 4 and Visit 3 for group 5 and 6) and for 2 months after the last vaccination.\n* History of Bell's palsy.\n* Ongoing regular use of intranasal sprays including corticosteroids and decongestants.\n* Ongoing cough, sinusitis, allergic rhinitis, nasal polyps or obstruction, including septum deviation significant enough to prevent bilateral administration of study vaccine.\n* Known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.\n* Subjects that are prone to nosebleed.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"39 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Cornelia Lif-Tiberg, MD","affiliation":"CTC","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Site 2","city":"Linköping","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"facility":"Site 1","city":"Uppsala","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Immunose™ FLU 1%,","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™\n\n15 µg HA/strain and 1% Endocine™: intranasal administration"},{"id":"FG001","title":"Immunose™ FLU 2%,","description":"15 µg HA/strain and 2% Endocine™\n\n15 µg HA/strain and 2% Endocine™: intranasal administration"},{"id":"FG002","title":"Influenza Antigen,","description":"15 µg HA/strain\n\n15 µg HA/strain: intranasal administration"},{"id":"FG003","title":"Saline (NaCl),","description":"Placebo\n\nPlacebo, Saline: intranasal administration"},{"id":"FG004","title":"i.m. Comparator,","description":"15 µg HA/strain\n\nintramuscular comparator: intramuscular administration"},{"id":"FG005","title":"i.n. Comparator","description":"intranasal comparator: intranasal administration"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"35"},{"groupId":"FG002","numSubjects":"36"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"18"},{"groupId":"FG005","numSubjects":"19"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"34"},{"groupId":"FG002","numSubjects":"35"},{"groupId":"FG003","numSubjects":"18"},{"groupId":"FG004","numSubjects":"17"},{"groupId":"FG005","numSubjects":"19"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Family reasons","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Immunose™ FLU 1%,","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™\n\n15 µg HA/strain and 1% Endocine™: intranasal administration"},{"id":"BG001","title":"Immunose™ FLU 2%,","description":"15 µg HA/strain and 2% Endocine™\n\n15 µg HA/strain and 2% Endocine™: intranasal administration"},{"id":"BG002","title":"Influenza Antigen,","description":"15 µg HA/strain\n\n15 µg HA/strain: intranasal administration"},{"id":"BG003","title":"Saline (NaCl),","description":"Placebo\n\nPlacebo, Saline: intranasal administration"},{"id":"BG004","title":"i.m. Comparator,","description":"15 µg HA/strain\n\nintramuscular comparator: intramuscular administration"},{"id":"BG005","title":"i.n. Comparator","description":"intranasal comparator: intranasal administration"},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"162"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"162"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.36","spread":"5.69"},{"groupId":"BG001","value":"26.34","spread":"5.46"},{"groupId":"BG002","value":"25.11","spread":"4.8"},{"groupId":"BG003","value":"27.72","spread":"5.6"},{"groupId":"BG004","value":"27.22","spread":"4.75"},{"groupId":"BG005","value":"24.68","spread":"4.32"},{"groupId":"BG006","value":"26.13","spread":"5.20"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"91"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"11"},{"groupId":"BG006","value":"71"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity","categories":[{"title":"African descent","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"}]},{"title":"Asian or Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}]},{"title":"Caucasian","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"17"},{"groupId":"BG004","value":"17"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"154"}]},{"title":"Mixed/multi-racial","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"4"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Sweden","categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"36"},{"groupId":"BG003","value":"18"},{"groupId":"BG004","value":"18"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"162"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Local Tolerability - First Dose","description":"Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Pre-dose, and 15 and 120 min after study drug administration (Visit 2).","groups":[{"id":"OG000","title":"Immunose™ FLU 1%,","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™\n\n15 µg HA/strain and 1% Endocine™: intranasal administration"},{"id":"OG001","title":"Immunose™ FLU 2%,","description":"15 µg HA/strain and 2% Endocine™\n\n15 µg HA/strain and 2% Endocine™: intranasal administration"},{"id":"OG002","title":"Influenza Antigen,","description":"15 µg HA/strain\n\n15 µg HA/strain: intranasal administration"},{"id":"OG003","title":"Saline (NaCl),","description":"Placebo\n\nPlacebo, Saline: intranasal administration"},{"id":"OG004","title":"i.m. Comparator,","description":"15 µg HA/strain\n\nintramuscular comparator: intramuscular administration"},{"id":"OG005","title":"i.n. Comparator","description":"intranasal comparator: intranasal administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"}]}]},{"title":"15 min post-dose","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"3"}]}]},{"title":"120 min post-dose","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"PRIMARY","title":"Local Tolerability - Second Dose (Group 1-4 Only)","description":"Local tolerability, as measured by at least one of the administration site reactions swelling, redness, pain and pruritus, regardless of severity.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Pre-dose, and 15 and 120 min after second study drug administration (Visit 3).","groups":[{"id":"OG000","title":"Immunose™ FLU 1%,","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™\n\n15 µg HA/strain and 1% Endocine™: intranasal administration"},{"id":"OG001","title":"Immunose™ FLU 2%,","description":"15 µg HA/strain and 2% Endocine™\n\n15 µg HA/strain and 2% Endocine™: intranasal administration"},{"id":"OG002","title":"Influenza Antigen,","description":"15 µg HA/strain\n\n15 µg HA/strain: intranasal administration"},{"id":"OG003","title":"Saline (NaCl),","description":"Placebo\n\nPlacebo, Saline: intranasal administration"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"18"}]}],"classes":[{"title":"Pre-dose","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"2"}]}]},{"title":"15 min post-dose","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"2"}]}]},{"title":"120 min post-dose","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose of IMP until the subject's last visit to the clinic (Visit 4 for Group 1 to 4 and Visit 3 for Group 5 and 6). In addition to collection of AEs at the clinic visits, solicited and unsolicited AEs were collected using a diary for 10 days after each dose administration. SAEs and AEs of special interest were also collected during 6 months after the last vaccination.","eventGroups":[{"id":"EG000","title":"Immunose™ FLU 1%,","description":"15 µg haemagglutinin(HA)/strain and 1% Endocine™\n\n15 µg HA/strain and 1% Endocine™: intranasal administration","deathsNumAffected":0,"deathsNumAtRisk":36,"seriousNumAffected":2,"seriousNumAtRisk":36,"otherNumAffected":32,"otherNumAtRisk":36},{"id":"EG001","title":"Immunose™ FLU 2%,","description":"15 µg HA/strain and 2% Endocine™\n\n15 µg HA/strain and 2% Endocine™: intranasal administration","deathsNumAffected":0,"deathsNumAtRisk":35,"seriousNumAffected":0,"seriousNumAtRisk":35,"otherNumAffected":30,"otherNumAtRisk":35},{"id":"EG002","title":"Influenza Antigen,","description":"15 µg HA/strain\n\n15 µg HA/strain: intranasal administration","deathsNumAffected":0,"deathsNumAtRisk":36,"seriousNumAffected":0,"seriousNumAtRisk":36,"otherNumAffected":26,"otherNumAtRisk":36},{"id":"EG003","title":"Saline (NaCl),","description":"Placebo\n\nPlacebo, Saline: intranasal administration","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":10,"otherNumAtRisk":18},{"id":"EG004","title":"i.m. Comparator,","description":"15 µg HA/strain\n\nintramuscular comparator: intramuscular administration","deathsNumAffected":0,"deathsNumAtRisk":18,"seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":13,"otherNumAtRisk":18},{"id":"EG005","title":"i.n. Comparator","description":"intranasal comparator: intranasal administration","deathsNumAffected":0,"deathsNumAtRisk":19,"seriousNumAffected":0,"seriousNumAtRisk":19,"otherNumAffected":10,"otherNumAtRisk":19}],"seriousEvents":[{"term":"Eryipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Gastroenteritis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]}],"otherEvents":[{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":36},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":35},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Dry throat","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":19}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":15,"numAtRisk":36},{"groupId":"EG001","numEvents":31,"numAffected":20,"numAtRisk":35},{"groupId":"EG002","numEvents":19,"numAffected":13,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":9,"numAffected":7,"numAtRisk":19}]},{"term":"Nasal discomfort","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Nasal dryness","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Nasal muscosal disorder","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":36},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":35},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":36},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Nasal pruritus","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":36},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":35},{"groupId":"EG002","numEvents":14,"numAffected":8,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":15,"numAtRisk":36},{"groupId":"EG001","numEvents":23,"numAffected":13,"numAtRisk":35},{"groupId":"EG002","numEvents":16,"numAffected":10,"numAtRisk":36},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":18},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pharyngeal oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Rhinalgia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":36},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":35},{"groupId":"EG002","numEvents":9,"numAffected":6,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":36},{"groupId":"EG001","numEvents":20,"numAffected":12,"numAtRisk":35},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":36},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":19}]},{"term":"Sinus pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Sneezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":36},{"groupId":"EG001","numEvents":15,"numAffected":8,"numAtRisk":35},{"groupId":"EG002","numEvents":17,"numAffected":12,"numAtRisk":36},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":19}]},{"term":"Throat irritation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":22,"numAtRisk":36},{"groupId":"EG001","numEvents":38,"numAffected":21,"numAtRisk":35},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":19}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":10,"numAtRisk":36},{"groupId":"EG001","numEvents":17,"numAffected":10,"numAtRisk":35},{"groupId":"EG002","numEvents":17,"numAffected":14,"numAtRisk":36},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":18},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":18},{"groupId":"EG005","numEvents":8,"numAffected":6,"numAtRisk":19}]},{"term":"Application site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Application site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":36},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":35},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":19}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":13,"numAtRisk":36},{"groupId":"EG001","numEvents":22,"numAffected":13,"numAtRisk":35},{"groupId":"EG002","numEvents":22,"numAffected":14,"numAtRisk":36},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":18},{"groupId":"EG004","numEvents":8,"numAffected":8,"numAtRisk":18},{"groupId":"EG005","numEvents":6,"numAffected":4,"numAtRisk":19}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site hypoaesthesia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site paraesthesia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":6,"numAffected":4,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":36},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":36},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Oral discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Oral pruritus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Hyperhidrosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":35},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":36},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Pruritus generalised","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":5,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":36},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":35},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Trismus","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":19}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":36},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (19.1)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":36},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":35},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":36},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":18},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":18},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":19}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":true},"pointOfContact":{"title":"Anna-Karin Maltais","organization":"Eurocine Vaccines AB","email":"annakarin.maltais@eurocine-vaccines.com","phone":"+46 76 233 81 62"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2016-06-30","uploadDate":"2018-10-08T04:27","filename":"Prot_SAP_000.pdf","size":12082532}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000627256","term":"Endocine"},{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}